Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
58
CSWYY Quote, Financials, Valuation and Earnings
Last price:
$19.25
Seasonality move
:
0.85%
Day range:
$19.25 - $19.25
52-week range:
$18.53 - $19.25
Dividend yield:
6.7%
P/E ratio:
5.52x
P/S ratio:
1.67x
P/B ratio:
0.71x
Volume:
--
Avg. volume:
--
1-year change:
3.89%
Market cap:
$727.1M
Revenue:
$436.2M
EPS (TTM):
$3.49
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, China Shineway Pharmaceutical Group Ltd. has -- downside to fair value with a price target of -- per share.
CSWYY vs. S&P 500
-
Over the past 5 trading days, China Shineway Pharmaceutical Group Ltd. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
China Shineway Pharmaceutical Group Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
China Shineway Pharmaceutical Group Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter China Shineway Pharmaceutical Group Ltd. reported revenues of --.
Earnings Growth
-
China Shineway Pharmaceutical Group Ltd. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter China Shineway Pharmaceutical Group Ltd. reported earnings per share of --.
Enterprise value:
-116.8M
EV / Invested capital:
--
Price / LTM sales:
1.67x
EV / EBIT:
-0.73x
EV / Revenue:
-0.22x
PEG ratio (5yr expected):
0.76x
EV / Free cash flow:
-1.02x
Price / Operating cash flow:
5.41x
Enterprise value / EBITDA:
-0.73x
Gross Profit (TTM):
$315.1M
Return On Assets:
8.57%
Net Income Margin (TTM):
30.23%
Return On Equity:
11.58%
Return On Invested Capital:
11.1%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Income Statement | ||||||
| Revenue | $306.8M | $338M | $355.8M | $181.1M | $186.1M | |
| Gross Profit | $201.3M | $220.7M | $239.9M | $118.5M | $126.7M | |
| Operating Income | $117.2M | $102.7M | $112.2M | $55.8M | $58.9M | |
| EBITDA | $128M | $115.7M | $128.7M | $80.4M | $89.5M | |
| Diluted EPS | $2.81 | $2.47 | $2.70 | $1.13 | $1.19 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $894.1M | $983.1M | $1.2B | $1.2B | -- | |
| Total Assets | $1.1B | $1.2B | $1.4B | $1.4B | -- | |
| Current Liabilities | $172.3M | $241.4M | $343.3M | $335.6M | -- | |
| Total Liabilities | $204.3M | $268M | $358.2M | $352.7M | -- | |
| Total Equity | $925.9M | $925.1M | $992.4M | $1B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-06-30 | 2012-06-30 | 2013-06-30 | 2012-06-30 | 2013-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $70.5M | $103.7M | $109.5M | $49.8M | $54.3M | |
| Cash From Investing | -$46.7M | -$36.2M | -$43.2M | -$22.3M | -$15.6M | |
| Cash From Financing | -$48.3M | -$49.1M | -$42.6M | -$33.8M | -$27.9M | |
| Free Cash Flow | $1.4M | $40.5M | $60.8M | $18.6M | $32.9M | |
CSWYY
Sector
Market Cap
$727.1M
--
Price % of 52-Week High
--
--
Dividend Yield
6.7%
--
Shareholder Yield
6.7%
--
1-Year Price Total Return
3.89%
--
Beta (5-Year)
0.669
--
Dividend yield:
6.7%
Annualized payout:
$1.29
Payout ratio:
38.67%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$19.25
200-day SMA
Sell
Level
$19.25
Bollinger Bands (100)
Sell
Level
19.25 - 19.25
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$19.25
Relative Strength Index (RSI14)
Buy
Level
100.00
ADX Line
Neutral
Level
Williams %R
Sell
Level
0
50-day SMA
Sell
Level
$19.25
MACD (12, 26)
Buy
Level
4.29
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.535)
Buy
CA Score
(Annual)
Level (1.0741)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-3.007)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
China Shineway Pharmaceutical Group Ltd. is an investment holding company, which engages in the research and development, manufacturing, and trading of Chinese pharmaceutical products. Its products include Shen Mai injection, Qing Kai Ling injection, and Wu Fu Xin Nao Qing soft capsule. The company was founded by Zhen Jiang Li and Yun Xia Xin on August 14, 2002 and is headquartered in Shijiazhuang, China.
Stock Forecast FAQ
In the current month, CSWYY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSWYY average analyst price target in the past 3 months is --.
-
Where Will China Shineway Pharmaceutical Group Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that China Shineway Pharmaceutical Group Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About China Shineway Pharmaceutical Group Ltd.?
Analysts are divided on their view about China Shineway Pharmaceutical Group Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that China Shineway Pharmaceutical Group Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is China Shineway Pharmaceutical Group Ltd.'s Price Target?
The price target for China Shineway Pharmaceutical Group Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSWYY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for China Shineway Pharmaceutical Group Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CSWYY?
You can purchase shares of China Shineway Pharmaceutical Group Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase China Shineway Pharmaceutical Group Ltd. shares.
-
What Is The China Shineway Pharmaceutical Group Ltd. Share Price Today?
China Shineway Pharmaceutical Group Ltd. was last trading at $19.25 per share. This represents the most recent stock quote for China Shineway Pharmaceutical Group Ltd.. Yesterday, China Shineway Pharmaceutical Group Ltd. closed at $19.25 per share.
-
How To Buy China Shineway Pharmaceutical Group Ltd. Stock Online?
In order to purchase China Shineway Pharmaceutical Group Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CSWYY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CSWYY
Sector
P/E ratio
5.52x
--
PEG ratio
0.76x
--
P/B ratio
0.71x
--
Price / LTM sales
1.67x
--
Growth Metrics
CSWYY
Sector
Revenue growth
--
--
Earnings growth
--
--
Revenue (5-year growth)
2.54%
--
Earnings forecast
--
--
Profitability
CSWYY
Sector
Profitability FY 2025
$315.3M
--
Return on invested capital
11.1%
--
Return on assets
8.57%
--
Return on equity
11.58%
--
Earnings Date
Last Earnings Date
Apr
5
Next Earnings Date
Apr
5
Estimated Next Earnings Date
Jul
5
Balance Sheet
CSWYY
Sector
Total cash
$889M
--
Short term investments
$47.9M
--
Total assets
$1.5B
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
